Search Results - "VIDRIALES, Belén"

Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma by Flores-Montero, Juan, de Tute, Ruth, Paiva, Bruno, Perez, José Juan, Böttcher, Sebastian, Wind, Henk, Sanoja, Luzalba, Puig, Noemí, Lecrevisse, Quentin, Vidriales, María Belén, van Dongen, Jacques J. M., Orfao, Alberto

“…In recent years, several studies on large series of multiple myeloma (MM) patients have demonstrated the clinical utility of flow cytometry monitoring of…”
Get full text

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma by Goicoechea, Ibai, Puig, Noemi, Cedena, Maria-Teresa, Burgos, Leire, Cordón, Lourdes, Vidriales, María-Belén, Flores-Montero, Juan, Gutierrez, Norma C., Calasanz, Maria-Jose, Ramos, Maria-Luisa Martin, Lara-Astiaso, David, Vilas-Zornoza, Amaia, Alignani, Diego, Rodriguez, Idoia, Sarvide, Sarai, Alameda, Daniel, Garcés, Juan José, Rodriguez, Sara, Fresquet, Vicente, Celay, Jon, Garcia-Sanz, Ramón, Martinez-Lopez, Joaquin, Oriol, Albert, Rios, Rafael, Martin-Sanchez, Jesus, Martinez-Martinez, Rafael, Sarra, Josep, Hernandez, Miguel-Teodoro, de la Rubia, Javier, Krsnik, Isabel, Moraleda, Jose-Maria, Palomera, Luis, Bargay, Joan, Martinez-Climent, Jose-Angel, Orfao, Alberto, Rosiñol, Laura, Mateos, Maria-Victoria, Lahuerta, Juan-José, Blade, Joan, San Miguel, Jesús, Paiva, Bruno

“…Patients with multiple myeloma (MM) carrying standard- or high-risk cytogenetic abnormalities (CAs) achieve similar complete response (CR) rates, but the later…”
Get full text

The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells by LOPEZ-CORRAL, Lucia, GUTIERREZ, Norma C, VIDRIALES, Maria Belén, MATEOS, Maria Victoria, RASILLO, Ana, GARCIA-SANZ, Ramón, PAIVA, Bruno, SAN MIGUEL, Jesus F

“…Genetic aberrations detected in multiple myeloma (MM) have also been reported in the premalignant conditions monoclonal gammopathy of undetermined significance…”
Get full text

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis by Paiva, Bruno, Mateos, María Victoria, Sanchez-Abarca, Luis Ignacio, Puig, Noemi, Vidriales, María-Belén, López-Corral, Lucía, Corchete, Luis A., Hernandez, Miguel T., Bargay, Joan, de Arriba, Felipe, de la Rubia, Javier, Teruel, Ana-Isabel, Giraldo, Pilar, Rosiñol, Laura, Prosper, Felipe, Oriol, Albert, Hernández, José, Esteves, Graça, Lahuerta, Juan José, Bladé, Joan, Perez-Simon, Jose Antonio, San Miguel, Jesús F.

“…There is significant interest in immunotherapy for the treatment of high-risk smoldering multiple myeloma (SMM), but no available data on the immune status of…”
Get full text

Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma by LUDWIG, Heinz, VITERBO, Luisa, ESTEVES, Graca, STOPPA, Anne Marie, ROBINSON, Don, RICCI, Deborah, CAKANA, Andrew, ENNY, Christopher, HUAIBAO FENG, DE VELDE, Helgi Van, HAROUSSEAU, Jean-Luc, GREIL, Richard, MASSZI, Tamas, SPICKA, Ivan, SHPILBERG, Ofer, HAJEK, Roman, DMOSZYNSKA, Anna, PAIVA, Bruno, VIDRIALES, María-Belén

“…Bortezomib-thalidomide-dexamethasone (VTD) is an effective induction therapy in multiple myeloma (MM). This phase II, noncomparative study sought to determine…”
Get full text

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy by MATEO, Gema, MONTALBDN, M. Angeles, DE LA RUBIA, Javier, DIAZ-MEDIAVILLA, Joaquin, SUREDA, Anna, RIBERA, José M, OJANGUREN, José M, DE ARRIBA, Felipe, PALOMERA, Luis, TEROL, Maria J, ORFAO, Alberto, SAN MIGUEL, Jesus F, VIDRIALES, Maria-Belen, LAHUERTA, Juan J, MATEOS, Maria V, GUTIERREZ, Norma, ROSINOL, Laura, MONTEJANO, Laura, BLADE, Joan, MARTINEZ, Rafael

“…To analyze the prognostic impact of immunophenotyping in patients with multiple myeloma (MM). We have prospectively analyzed the prognostic impact of antigenic…”
Get full text

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells by Pérez-Persona, Ernesto, Vidriales, María-Belén, Mateo, Gema, García-Sanz, Ramón, Mateos, Maria-Victoria, de Coca, Alfonso García, Galende, Josefina, Martín-Nuñez, Guillermo, Alonso, José M., de las Heras, Natalia, Hernández, José M., Martín, Alejandro, López-Berges, Consuelo, Orfao, Alberto, San Miguel, Jesús F.

“…Monoclonal gammopathy of uncertain significance (MGUS) and smoldering multiple myeloma (SMM) are plasma cell disorders with a risk of progression of…”
Get full text

Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma by González-Calle, Verónica, Cerdá, Seila, Labrador, Jorge, Sobejano, Eduardo, González-Mena, Beatriz, Aguilera, Carmen, Ocio, Enrique María, Vidriales, María Belén, Puig, Noemí, Gutiérrez, Norma Carmen, García-Sanz, Ramón, Alonso, José María, López, Rosa, Aguilar, Carlos, de Coca, Alfonso García, Hernández, Roberto, Hernández, José Mariano, Escalante, Fernando, Mateos, María-Victoria

“…Immunoparesis or suppression of polyclonal immunoglobulins is a very common condition in newly diagnosed myeloma patients. However, the recovery of polyclonal…”
Get full text

A phase 3 trial of azacitidine versus a semi‐intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia by Vives, Susana, Martínez‐Cuadrón, David, Bergua Burgues, Juan, Algarra, Lorenzo, Tormo, Mar, Martínez‐Sánchez, María Pilar, Serrano, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, López‐Lorenzo, José L., Gil, Cristina, Vidriales, Belén, Falantes, Jose F., Serrano, Alfons, Labrador, Jorge, Sayas, María J., Foncillas, María Á., Amador Barciela, María L., Olave, María Teresa, Colorado, Mercedes, Gascón, Adriana, Fernández, María Á., Simiele, Adriana, Pérez‐Encinas, Manuel M., Rodríguez‐Veiga, Rebeca, García, Olga, Martínez‐López, Joaquín, Barragán, Eva, Paiva, Bruno, Sanz, Miguel Á., Montesinos, Pau

“…BACKGROUND Options to treat elderly patients (≥65 years old) newly diagnosed with acute myeloid leukemia (AML) include intensive and attenuated chemotherapy,…”
Get full text

Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile by Martín-Martín, Lourdes, López, Antonio, Vidriales, Belén, Caballero, María Dolores, Rodrigues, António Silva, Ferreira, Silvia Inês, Lima, Margarida, Almeida, Sérgio, Valverde, Berta, Martínez, Pilar, Ferrer, Ana, Candeias, Jorge, Ruíz-Cabello, Francisco, Buadesa, Josefa Marco, Sempere, Amparo, Villamor, Neus, Orfao, Alberto, Almeida, Julia

“…Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare subtype of leukemia/lymphoma, whose diagnosis can be difficult to achieve due to its clinical…”
Get full text

Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients by PAIVA, Bruno, VIDRIALES, Maria-Belén, PEREZ, Jose J, MATEO, Gema, MONTALBAN, Maria Angeles, MATEOS, Maria Victoria, BLADE, Joan, LAHUERTA, Juan José, ORFAO, Alberto, SAN MIGUEL, Jesús F

“…Quantification of bone marrow plasma cells in multiple myeloma patients using conventional morphology is of limited prognostic value, while the merit of…”
Get full text

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma by Paiva, Bruno, Puig, Noemi, Cedena, Maria-Teresa, Rosiñol, Laura, Cordón, Lourdes, Vidriales, María-Belén, Burgos, Leire, Flores-Montero, Juan, Sanoja-Flores, Luzalba, Lopez-Anglada, Lucia, Maldonado, Roberto, de la Cruz, Javier, Gutierrez, Norma C, Calasanz, Maria-Jose, Martin-Ramos, Maria-Luisa, Garcia-Sanz, Ramón, Martinez-Lopez, Joaquin, Oriol, Albert, Blanchard, María-Jesús, Rios, Rafael, Martin, Jesus, Martinez-Martinez, Rafael, Sureda, Anna, Hernandez, Miguel-Teodoro, de la Rubia, Javier, Krsnik, Isabel, Moraleda, Jose-Maria, Palomera, Luis, Bargay, Joan, Van Dongen, Jacques J M, Orfao, Alberto, Mateos, Maria-Victoria, Blade, Joan, San-Miguel, Jesús F, Lahuerta, Juan-José

“…Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain,…”
Get full text

Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience by Sobas, Marta, Knopinska-Posluszny, Wanda, Piątkowska-Jakubas, Beata, García-Álvarez, Flor, Díez, María Elena Amutio, Caballero, Mar, Martínez-Cuadrón, David, Aguiar, Eliana, González-Campos, Jose, Garrido, Ana, Algarra, Lorenzo, Salamero, Olga, de la Serna, Javier, Sayas, Maria Jose, Perez-Encinas, Manuel Mateo, Vives, Susana, Vidriales, Belén, Labrador, Jorge, Prado, Ana Inés, Celebrin, Lucía, Mayer, Jiri, Brioso, Joana, de Laiglesia, Almudena, Bergua, Juan Miguel, Amigo, Maria Luz, Rodriguez-Medina, Carlos, Polo, Marta, Pluta, Agnieszka, Cichocka, Edyta, Skarupski, Marek, Sanz, Miguel A, Wierzbowska, Agnieszka, Montesinos, Pau

“…The most important challenges in acute promyelocytic leukemia (APL) is preventing early death and reducing long-term events, such as second neoplasms (s-NPLs)…”
Get full text

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up by Ludwig, Heinz, Greil, Richard, Masszi, Tamas, Spicka, Ivan, Shpilberg, Ofer, Hajek, Roman, Dmoszynska, Anna, Paiva, Bruno, Vidriales, María‐Belén, Esteves, Graca, Stoppa, Anne Marie, Robinson, Don, Chaturvedi, Shalini, Ataman, Ozlem, Enny, Christopher, Feng, Huaibao, Velde, Helgi, Viterbo, Luisa

“…Summary This follow‐up extension of a randomised phase II study assessed differences in long‐term outcomes between bortezomib‐thalidomide‐dexamethasone (VTD)…”
Get full text

Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells by Muntión, Sandra, Preciado, Silvia, Sánchez-Luis, Elena, Corchete, Luis, Díez-Campelo, María, Osugui, Lika, Martí-Chillón, Gerardo-Javier, Vidriales, María-Belén, Navarro-Bailón, Almudena, De Las Rivas, Javier, Sánchez-Guijo, Fermín

“…Background: Eltrombopag (EP) is a small molecule that acts directly on hematopoietic stem cells (HSCs) and megakaryocytes to stimulate the hematopoietic…”
Get full text

Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells by Pérez‐Persona, Ernesto, Mateo, Gema, García‐Sanz, Ramón, Mateos, María‐Victoria, De Las Heras, Natalia, De Coca, Alfonso García, Hernández, José M., Galende, Josefina, Martín‐Nuñez, Guillermo, Bárez, Abelardo, Alonso, José M., Martín, Alejandro, López‐Berges, Consuelo, Orfao, Alberto, San Miguel, Jesús F., Vidriales, María‐Belén

“…Summary The present study explored the impact of two novel criteria; having >95% abnormal plasma cells by flow cytometry at diagnosis and the evolving subtype…”
Get full text

Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients by Martín-Martín, Lourdes, Gutiérrez-Herrero, Sara, Herrero-García, María, Martín García-Sancho, Alejandro, Yeguas, Ana, Martín-López, Ana-África, López-Corral, Lucía, Pérez-López, Estefanía, García-Blázquez, Marta, Sánchez-Guijo, Fermín, Vidriales, María Belén, Gaipa, Giuseppe, Orfao, Alberto

Get full text

Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia by Ijurko, Carla, Romo-González, Marta, Prieto-Bermejo, Rodrigo, Díez-Campelo, María, Vidriales, María-Belén, Muntión, Sandra, Sánchez-Guijo, Fermín, Sánchez-Yagüe, Jesús, Hernández-Hernández, Ángel

“…Acute myeloid leukaemia (AML) is a highly heterogeneous malignancy, with a poor 5-year overall survival rate of approximately 30%. Consequently, the search for…”
Get full text

Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications by Morado, Marta, Freire Sandes, Alex, Colado, Enrique, Subirá, Dolores, Isusi, Paloma, Soledad Noya, María, Belén Vidriales, María, Sempere, Amparo, Ángel Díaz, José, Minguela, Alfredo, Álvarez, Beatriz, Serrano, Cristina, Caballero, Teresa, Rey, Mercedes, Pérez Corral, Ana, Cristina Fernández Jiménez, María, Magro, Elena, Lemes, Angelina, Benavente, Celina, Bañas, Helena, Merino, Juana, Castejon, Celine, Gutierrez, Olivier, Rabasa, Pilar, Vescosi Gonçalves, Matheus, Perez‐Andres, Martin, Orfao, Alberto

“…Background Although consensus guidelines have been proposed in 2010 for the diagnostic screening of paroxysmal nocturnal hemoglobinuria (PNH) by flow cytometry…”
Get full text

Blast Transformation of Chronic Myeloid Leukemia Driven by Acquisition of t(8;21)(q22;q22)/ RUNX1::RUNX1T1 : Selecting Optimal Treatment Based on Clinical and Molecular Findings by Fernández-Sánchez, Adolfo, Hernández-Sánchez, Alberto, De Ramón, Cristina, Chillón, María-Carmen, Vidriales, María Belén, Baile-González, Mónica, Fuentes-Morales, Cristina-Teresa, Sierra-Pacho, Magdalena, López-Corral, Lucía, Sánchez-Guijo, Fermín

“…The advent of tyrosine kinase inhibitors (TKIs) has changed the natural history of chronic myeloid leukemia (CML), and the transformation from the chronic…”
Get full text